A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

• Status: Terminated
• Trial end date: 2012-09-01

Summary

The primary objective was to evaluate and compare the efficacy of androgen deprivation with or without docetaxel as determined by the median progression free survival (PFS) over the period of 18-month therapy and at least 18-month follow-up.

The secondary objectives were:

• To assess cancer specific survival;

• To compare overall survival between the 2 treatment groups;

• To evaluate patient-reported outcomes including quality of life, fatigue, and sexual functioning as measured by 3 different assessments.

• Phase: Phase 3

Details

• Lead Sponsor: Sanofi
• Treatments: Androgens; Bicalutamide; Docetaxel; Leuprolide